AGER and chronic obstructive pulmonary disease: A further limitation of the potential biomarker role of sRAGE, not described in the abovementioned review, is its inverse relationship with disease activity of COPD, meaning that the plasma levels of sRAGE are decreasing with an increase in disease severity.